Novo Nordisk

Aniket Pujari September 27, 2026

Battle for Weight-Loss Dominance: Novo Nordisk Charts Next Phase as Eli Lilly Gains Ground in GLP-1 Race

Novo Nordisk is navigating a pivotal phase in the weight-loss market as competitor Eli Lilly gains market share with Zepbound. Explore how both pharmaceutical leaders…

Business

Aniket Pujari September 22, 2026

Eli Lilly Ramps Up Foundayo Production to Meet Surging Demand for Oral GLP-1 Weight-Loss Pills

Eli Lilly is expanding manufacturing for its oral weight-loss drug Foundayo after CEO David Ricks revealed one-third of new GLP-1 pill patients are choosing the…

Business

Aniket Pujari September 14, 2026

Novo Rebrands and Refines Global Strategy as Race for Obesity Market Dominance Escalates

Novo Nordisk unveils a major corporate rebranding to Novo as CEO Mike Doustdar outlines a revised obesity strategy to address rising competition from Eli Lilly.

Battle for Weight-Loss Dominance: Novo Nordisk Charts Next Phase as Eli Lilly Gains Ground in GLP-1 Race

Eli Lilly Ramps Up Foundayo Production to Meet Surging Demand for Oral GLP-1 Weight-Loss Pills

Novo Rebrands and Refines Global Strategy as Race for Obesity Market Dominance Escalates

You Missed

Feline Economy Flourishes: How Rising Cat Ownership and Premium Spending Are Reshaping Pet Retail

Severed Verizon Fiber Cable Causes Massive Air Traffic Delays Across East Coast Airports

McDonald’s Investor Day: 4 Key Priorities as the Fast-Food Giant Navigates U.S. Sales Headwinds

McDonald’s Shares Dip as Fast-Food Giant Outlines Costly ‘NEXT’ Growth Strategy